Synvitta Targets Diagnostic Revolution: Faster Answers in One Test

ALACHUA – A biotechnology startup based in Alachua is positioning itself to reshape how medical tests are performed, announcing a new leadership partnership and an ambitious push into advanced diagnostic technology.

Synvitta Diagnostics, Inc. said it is focused on advancing multiplex diagnostic testing, a method that allows multiple biomarkers to be detected in a single test, with the goal of creating faster, more efficient and widely accessible diagnostic tools.

The announcement highlights a partnership between co-founder and Chief Executive Officer Mitch Glaeser and co-founder and Chief Scientific Officer Rainara Almeida, combining business development experience with scientific research expertise.

Glaeser, who also founded Alachua’s San Felasco Tech City, has been a prominent figure in the region’s technology and startup ecosystem. The campus has served as a hub for emerging companies and collaborative research, particularly in biotechnology and sustainability-focused ventures.

“Synvitta represents a powerful combination of innovation and entrepreneurship,” Glaeser said. “The ability to deliver multiplex diagnostics in a simple and scalable format creates a significant opportunity across multiple areas of healthcare.”

Company officials say Synvitta is developing a platform that integrates both rapid single-target tests and scalable multiplex systems, allowing laboratories to analyze multiple conditions at once. The approach is designed to streamline workflows, reduce processing time and improve diagnostic accuracy in clinical settings.

Almeida said the company’s focus is on improving both the speed and precision of testing while maintaining accessibility for healthcare providers.

“Our mission is to make diagnostics more precise, faster, and accessible,” Almeida said. “We are building a platform that simplifies complex testing while maintaining high analytical performance, enabling better and faster clinical decision-making.”

Looking ahead, the company plans to expand its diagnostic offerings to include applications for infectious diseases, autoimmune conditions and neurodegenerative disorders. Officials say the technology is intended to address gaps in current testing capabilities and support improved patient outcomes.

Synvitta is currently operating out of UF Innovate | Sid Martin Biotech, where it is advancing product development and working with clinical and strategic partners in the United States and abroad.

Company leaders said their goal is to integrate new diagnostic tools into existing laboratory systems without adding complexity, while maintaining high levels of sensitivity and reliability.

With its combination of proprietary technology and leadership experience, Synvitta is aiming to establish itself as a key player in the evolving field of clinical diagnostics.

#     #     #

email editor@

alachuatoday.com